Skip to content

Cardlytics rallies after earnings growth but volatility and risk remain

Cardlytics rallies after earnings growth but volatility and risk remain
Dino Kurbegovic

Cardlytics (NASDAQ: CDLX) was up 6% in premarket trading on Tuesday, May 3 after the company reported an estimate beat in the first-quarter earnings results. The shares were trading strong throughout the day, only to crash by 7.85% in after-hours trading. 

The company reported revenue of $67.9 million, a 27.6% increase year-over-year (YoY) with gross profit rising 34% YoY by $26.2 million. Additionally, earnings per share (EPS) was -$0.38 which beat estimates by $0.17.   

During the presentation call, an interesting note was mentioned which relates to major banks doubling their investments into CLDX which could bode well for the future. 

Source: Twitter 

A lot of good updates 

Cardlytics showed tremendous growth sharing opportunities to cross-sell and increase partnerships with various clients, these updates will likely see the company be cash-flow positive by the end of 2023 or by the second half of 2023. Though these are their own estimations, however, if the company keeps posting high revenue numbers this just might be the case.

Shares of the company have been devastated from August 2021 onwards, with high selling pressure coming in and knocking down shares by over 30%. Year-to-date the shares are down 45% trading below all daily Simple Moving Averages

There is a lot of sell volume coming in for the shares keeping them sub $40 and if the shares can break above there could potentially be more upside. It will be difficult for the shares to cover ground to $50 which should be the next resistance line.  

 CDLX 20-50-200 SMA lines chart. Source. Finviz.com data. See more stocks here.

Elsewhere, analysts give the shares a moderate buy rating predicting that in the next 12 months on average the shares should be trading around $57. This would represent a potential upside of 51.60% from the current price of $37.60, if more buying pressure comes in these numbers could be realistic for 2022, especially if more positive earnings surprises come along.

Source: TipRanks

Despite having a challenging few quarters behind them CDLX seems to be heading in the right direction. The earnings call highlighted some major developments, solid earnings, and potential benefits in the future for shareholders. 

Staying or entering positions in companies like Cardlytics will require gauging one’s risk appetite since the shares tend to move up and down in wide margins possibly causing investors to have an emotional reaction to the price action. 

If and when this occurs usually investors close out positions and take a loss, so doing research and understanding risk appetites is the best way to make a play on this company. 

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk. 

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.